An Open Label Clinical Study to Evaluate the efficacy of Menohelp in Asrigdara W.S.R. to Abnormal Uterine Bleeding (AUB)

Magnet Labs under Mankind Pharma0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

研究概览

暂无简介。

•1. Women of reproductive age group 18-45 years.
•2. Excessive bleeding during menstruation (menstrual blood loss > 80 ml in 1-7 days) or having Pictorial blood loss assessment chart (PBLAC) score more than 100 points for 2 consecutive cycles.
•3.Prolonged menstrual bleeding (With the duration of bleeding >7 days) Inter menstrual bleeding
•4.Frequent menstrual cycle (interval < 21 days)
•5.Patients who are willing to go for relevant investigation
•6.Normal gynaecological examination and PAP smear

•Patients with any diagnosed uterine organic pathology like Adenomyosis, and chronic tubo ovarian mass.
•Submucosal or intramural fibroids, or subcervical fibroids greater than 3cm.
•Patients with systemic diseases like hypertension, diabetic mellitus, congestive cardiac failure etc.
•Patients with coagulopathy, liver and thyroid dysfunction etc.
•Patient with malignancy or undiagnosed neoplasm.
•Patients with history of recent abortion.
•Patients with active genital tuberculosis.
•Bleeding from the polyps and erosion.
•IUCD in utero, pelvic endometriosis.
•Hb < 8 gm/dl

发起方

Magnet Labs under Mankind Pharma